Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ)
Pneumologie · 2024-11 · 78 (11) · 912-921
DOI: 10.1055/a-2346-9840 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pneumologie, online erschienen am 11.07.2024. Verfasst von Frank Kanniess und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gemeinschaftspraxis Reinfeld, Reinfeld, Germany. Hauptthemen laut MEDLINE: Asthma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Germany.
Abstract (Originalsprache)
Background
The Asthma Impairment and Risk Questionnaire (AIRQ), a 10-item, equally weighted, yes/no tool assessing symptom impairment and risk of exacerbations in patients with asthma aged ≥12 years, was developed and validated in a US patient population to evaluate varying levels of asthma control. This study aimed to validate the German language version of the AIRQ in patients aged ≥12 years with different levels of asthma control.
Methods
A cross-sectional, observational, multi-centre study comprising a single visit was conducted in multiple specialised asthma centres and general practices in Germany. A total of 300 patients completed the following measures: 1) Patient Sociodemographic and Clinical Questionnaire, 2) AIRQ, 3) Asthma Control Test (ACT), and 4) Asthma Control Questionnaire (ACQ-6). Logistic regression analyses were conducted to assess the AIRQ score cut points with the greatest predictive validity in discriminating between different control levels relative to a standard of ACT plus prior-year exacerbations or ACQ-6 plus prior-year exacerbations.
Results
The German version of the AIRQ demonstrated a robust capability to correctly identify well-controlled versus not well- or very poorly controlled (AUC values of 0.90 or higher) and well- or not well-controlled versus very poorly controlled asthma (AUC values of 0.89 or higher).
Conclusions
The German version of the AIRQ is a suitable tool to identify adults with varying levels of asthma control, which in turn can help to accurately identify patients with uncontrolled asthma in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gemeinschaftspraxis Reinfeld, Reinfeld, Germany.
- Respiratory and Immunology, AstraZeneca Germany, Hamburg, Germany.
- Pneumology, University of Rostock, Rostock, Germany.
- MECS Research GmbH, Berlin, Germany.
- Pneumologicum Hamburg, Hamburg, Germany.
- Pneumologische Gemeinschaftspraxis, Koblenz, Germany.
ORCID-Profile: Fabian Höing
Förderung
- AstraZeneca Germany
Zitieren
APA
Kanniess, F., Defosse, K., Lommatzsch, M., Schultz, T., Timmermann, H., Schmidt, O., Heindl, S., Baumann, H. J., Buhl, R., Taube, C., Höing, F., & Korn, S. (2024). Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ). Pneumologie, 78(11), 912-921. https://doi.org/10.1055/a-2346-9840
Vancouver
Kanniess F, Defosse K, Lommatzsch M, Schultz T, Timmermann H, Schmidt O, et al. Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ). Pneumologie. 2024;78(11):912-921. doi:10.1055/a-2346-9840
BibTeX
@article{Kanniess2024,
author = {Kanniess, Frank and Defosse, Kerstin and Lommatzsch, Marek and Schultz, Thomas and Timmermann, Hartmut and Schmidt, Olaf and Heindl, Stefan and Baumann, Hans Jörg and Buhl, Roland and Taube, Christian and Höing, Fabian and Korn, Stephanie},
title = {Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ)},
journal = {Pneumologie},
year = {2024},
volume = {78},
number = {11},
pages = {912--921},
doi = {10.1055/a-2346-9840}
}
EUVIMED